A Study of Complement 3 Glomerulopathy (C3G) Patients Treated With Iptacopan Through an Early Access Program in Spain

ConditionComplement 3 Glomerulopathy

Trial statusNot yet recruiting

Trial phaseNot listed

Trial typeObservational

Biological sexAll

Age18-100

SponsorNovartis Pharmaceuticals

About this trial

This study aims to characterize the patient profiles and the clinical experience of iptacopan treatment in adult patients with C3G treated through an early access program (EAP) in Spain.

Eligibility criteria

Qualifiers

Adult patients (≥18 years).

Biopsy-confirmed C3G.

Patients who have received at least one dose of iptacopan through an EAP from October 2020 to June 2025.

Disqualifiers

None

Trial design

Treatments tested in this trial

Not listed

Trial groups

35 Participants

are grouped into 1 trial group

Locations

This trial has no locations

Sponsors and collaborators

Novartis Pharmaceuticals

Lead sponsor

Source ClinicalTrials.gov